



(51) International Patent Classification:
C07K 14/005 (2006.01) C12N 15/86 (2006.01)
A61K 35/76 (2015.01)

(21) International Application Number:
PCT/US2024/029331

(22) International Filing Date:
14 May 2024 (14.05.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/466,579 15 May 2023 (15.05.2023) US

(71) Applicant: SANGAMO THERAPEUTICS, INC.
[US/US]; 501 Canal Blvd., Suite A100, Richmond, California 94804 (US).

(72) Inventors: OJALA, David; c/o Sangamo Therapeutics, Inc., 501 Canal Blvd., Suite A100, Richmond, California 94804 (US). TIFFANY, Matthew; c/o Sangamo Therapeutics, Inc., 501 Canal Blvd., Suite A100, Richmond, California 94804 (US).

(74) Agent: WURSTER, April; 1 East Washington Street, Suite 2700, Phoenix, Arizona 85004 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: FITNESS MATURATION OF ENGINEERED AAV CAPSID STAC-102

Fitness maturation of capsid STAC-102




FIG. 1

(57) Abstract: This application relates to engineering AAV capsids, for example, STAC-102. In some embodiments, the engineered AAV capsids mediate delivery to the central nervous system.

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:
02 January 2025 (02.01.2025)